BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) the manufacturer of KALBITOR®(ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older, has announced the launch of its HAE genetic counseling program. The program, which is available to all members of the HAE community, provides diagnosed HAE patients and their family members with a free counseling session.
